drugset / Trial / NCT01730638
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
Phase 1/2
Completed
25 enrolled
Nantes University Hospital
Gilead Sciences · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The aim of this study is to optimize pretargeting parameters using pharmacokinetic and imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288 peptide in MTC patients with abnormal Ct serum level after initial complete surgery and at least one abnormal lesion
Timeline
- Start
- 2013-01
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68 Ga-IMP-288 | Peptide | 1.5 unknown | — |
| Subject | 68 Ga-IMP-288 | Peptide | 6 unknown | — |
| Subject | 68 Ga-IMP-288 | Peptide | 150 mbq | — |
| Subject | TF2 | Monoclonal antibody | 30 unknown | — |
| Subject | TF2 | Monoclonal antibody | 120 unknown | — |